论文信息 - A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer - 字舞流文

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

B. Monk | P. Thaker | D. Silasi | A. Mendivil | J. Scalici | D. O’Malley | S. Chambers | K. Tewari | W. Graybill | S. Ghamande | P. Lim | K. Moore | Megan D. Indermaur | S. Crafton | Sarfraz Ahmad | Eskander N. Ramez | D. Richardson | Michael Mchale | Robert W Holloway | Ahmed N Al-Niaimi | James Barter | Tiffany Beck | Robert L Coleman | Erin Crane | Thomas Herzog | Veena S John | Lisa Landrum | Joseph A Lucci | Robert Morris | Thomas J Reid | Peter G Rose | Edward W Wang | Robert L. Coleman | Sarfraz Ahmad | Thomas J Herzog | Sarfraz Ahmad | Thomas J. Herzog | L. Landrum | Thomas Reid | A. N. Al-Niaimi | James F. Barter | Erin K Crane | Joseph A. Lucci | Edward Wang